Phase I Drug-drug Interaction of Omega-3 and Atorvastatin
Status:
Unknown status
Trial end date:
2018-08-31
Target enrollment:
Participant gender:
Summary
This study evaluates the safety and pharmacokinetic drug-drug interactions of omega-3 and
atorvastatin in healthy male volunteers. Half of the participants will receive omega-3 for 16
days to be steady state of omega-3 and followed by omega-3 and atorvastatin in combination
for 7 days. The other half will receive Atorvastatin for 7 days to be steady state of
Atorvastatin, and followed by Atorvastatin and Omega-3 in combination for 16 days.